WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

CNBC's Bertha Coombs asks President Trump and his team at the White House's announcement on lower prices for Eli Lilly and ...

As you might expect, the competition to win a share of the expanding GLP-1 market is fierce right now, with giants Novo ...

A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor ...

Working alongside primary care physicians, hospitalists, and other clinicians, pharmacists help ensure more seamless handoff ...

It's impossible to avoid headlines about GLP-1 medications. The weight-loss drugs target hormones in the gut and brain that ...

As Pfizer acquires MET-097 maker Metsera, phase 2 data show potential for greater tolerability and once-monthly dosing.

Study also revealed no increased risk for major adverse cardiovascular events for patients on a GLP-1 RA versus those not on a GLP-1 RA.

The rise of GLP-1 weight loss drugs has been a game-changer for the grocery sector, and the dairy segment appears ...

"We're excited to bring our High Protein Nutrition Shakes to Walmart and make high-quality, plant-based nutrition even more accessible," said Tom Beecher, President of Kate Farms. "In 2024, the U.S.

GLP-1 receptor agonists — the drug class that includes Ozempic, Wegovy and Mounjaro — were linked to improved survival among colon cancer patients in a new observational study from UC San Diego.